Startups
National Institute of Neurological Disorders and Stroke
The National Institute of Neurological Disorders and Stroke (NINDS) is the United States NIH component supporting research on the brain, nervous system and neurological disease. Congress created its predecessor in1950 as the National Institute of Neurological Diseases and Blindness; the current name dates to1988. The exact ninds.nih.gov public institution is represented separately from its NIH parent, other NIH institutes, private foundations and individual researchers. The authentic NIH institutional mark is shared parent branding, expressly qualified here; it is not presented as a separate NINDS-specific seal. Its activities encompass basic neuroscience, intramural laboratory and clinical research, extramural grants, neural technology, translational drug/device development and neurological clinical research. Relevant programmes include SBIR/STTR, Blueprint Neurotherapeutics, IGNITE and the cross-NIH BRAIN Initiative. Programme allocations and Congressional appropriations are agency budgets, not LP fund raises; awards are not equity investments or proof of recipient bank disbursement. No private venture funds or corporate cash raises are invented. The public profile captures all nine currently named institute leaders, the acting chief of staff and four publicly listed small-business programme contacts: fourteen individually sourced people and fourteen scoped roles. Acting titles are retained. Amy Bany Adams is the current acting director, with an official January2026 transition source; the existing AmyAdams NIH person and outside NIH role are preserved. Emily Caporello is explicitly last-published/former because newer first-person evidence reports her move to FDA, despite the older programme-contact page still naming her. Seven genuine individually attributed portraits were recovered from NINDS, NIH intramural research, a former employer and original professional speaker/physician publishers. Seven others remain explicit source/access gaps; generic placeholders are excluded. The wider451-entry staff directory and external advisory council are not asserted as a complete employee census or current appointments where terms/access cannot be verified. The investment relationship graph can represent exact administered research-award notices, separately from equity. NIH RePORTER identifies five distinct annual NINDS-administered Synapticure awards under NS124457, NS134458 and NS143521, with exact recipient legal identity and notice dates. Published annual award amounts are obligations/awards, not additional cumulative headline cash or confirmed paid bank cash. The sole Synapticure issuer owner maintains those five relationships; no duplicate NIH-parent allocation or personal leader check is inferred.
Founded 1950
Team
Alynda WoodActing Chief of Staff |
 Amir TamizAssociate Director for Translational Research / Director, Division of Translational Research |
 Amy AdamsActing Director |
Andrea MeredithAssociate Director for Extramural Activities / Director, Division of Extramural Activities |
Annette GilchristProgram Director, Drug Development, Small Business Program |
 Avindra NathClinical Director, Division of Intramural Research |
 Clinton WrightAssociate Director for Clinical Research / Director, Division of Clinical Research |
Emily CaporelloFormer / last-published Director, NINDS Small Business Program |
 Jeffrey DiamondScientific Director, Division of Intramural Research |
Jessica ForbesScientific Program Manager, Small Business Program |
Jill R. HarperActing Deputy Director for Scientific Management and Operations / Acting Executive Officer |
 John NgaiDirector, NIH BRAIN Initiative |
 Patrick BellgowanActing Associate Director for Neuroscience |
Taryn AubrechtProgram Director, Clinical and Research Tools, Small Business Program |
